Three-year results of ST-segment elevation myocardial infarction patients treated with a prespecified bioresorbable vascular scaffold implantation strategy: bVS STEMI STRATEGY-IT long-term

Coronary artery disease: novel insights in a long-standing disease

“…Randomized trials comparing Absorb bioresorbable vascular scaffold (BVS) with everolimus-eluting stents (EES) demonstrated higher adverse event rates with Absorb within the first 3 years but similar outcomes over the long term. The poor early results have been attributed to the BVS thick struts and suboptimal implantation technique 30 . The BioFreedom polymer-free biolimus-A9-eluting stent (PF-BES) has shown promising results in patients carrying high bleeding risk.…”

“…The poor early results have been attributed to the BVS thick struts and suboptimal implantation technique. 30 The BioFreedom polymer-free biolimus-A9-eluting stent (PF-BES) has shown promising results in patients carrying high bleeding risk. A total of 1104 patients from the RUDI-FREE, which included patients undergoing PCI with PF-BES in routine clinical practice, were stratified into three groups according to their renal function.…”